Novo Nordisk shares climb after positive results for anti-obesity pill

Novo Nordisk's shares surged by approximately £9 billion following promising trial results for its new anti-obesity pill, Wegovy. The research indicates that the tablet version of Wegovy can lead to significant weight loss, which is a major breakthrough in obesity treatment. This development is crucial as it not only boosts the company's market value but also offers hope for millions struggling with obesity, highlighting the potential for effective pharmaceutical solutions in managing this global health issue.